Moth Bean Peptides That Block the Blood Pressure Enzyme: From Lab to Rats

What the researchers found

Researchers extracted peptides from moth bean seeds using six different enzymes and found that alcalase produced the most effective ACE-inhibiting fragments. The most potent peptide fraction inhibited ACE at just 11.19 ± 0.15 μg/mL. Four specific peptides (IAWDFR, ADLPGLK, DKPWWPK, and AVIPNAPNLR) were identified through mass spectrometry, with molecular docking showing two bind to active sites and two to non-active sites of the ACE molecule.

In live testing, the moth bean protein hydrolysate lowered systolic blood pressure in hypertensive rats from 155 ± 3.13 mmHg (control) to 125 ± 0.76 mmHg — a 30 mmHg reduction.

Why it matters

ACE inhibitor drugs are a cornerstone of blood pressure treatment but come with side effects like dry cough. Finding natural ACE-inhibiting peptides in common food legumes could eventually lead to functional foods or nutraceuticals that help manage blood pressure with fewer side effects.

The numbers in context

ACE inhibition IC50: 11.19 ± 0.15 μg/mL · SBP reduced: 155 → 125 mmHg · 30 mmHg drop · 4 peptides identified

How the study worked

Moth bean seed protein was extracted and hydrolyzed with six enzymes (alcalase, chymotrypsin, flavourzyme, papain, pepsin, trypsin). The most active hydrolysate was purified by FPLC and analyzed by mass spectrometry. Molecular docking simulated peptide binding to ACE. In vivo testing used dexamethasone-induced hypertensive rats.

Who was studied

Dexamethasone-induced hypertensive rats (in vivo); in vitro enzyme and molecular docking analyses

What this study cannot tell us

This is an animal study — the blood pressure effects were shown in rats with chemically induced hypertension, which may not translate directly to human essential hypertension. The peptides were tested as a hydrolysate mixture rather than as isolated pure peptides in the in vivo portion. No toxicity or long-term safety data was reported.

How to read the evidence

Rated preliminary because this combines in vitro enzyme assays with a small animal study. While the ACE inhibition data and molecular docking are solid, the blood pressure findings are from chemically induced hypertension in rats, which is an early step on the path to clinical relevance.

When this study was published

Published in 2023, this is recent research in the active field of food-derived bioactive peptides. The findings are relevant but still at the preclinical stage.

The bigger picture

Food-derived ACE-inhibiting peptides are a growing area of nutraceutical research, with peptides from milk, fish, and soy already well-studied. This work adds moth bean — an affordable, drought-resistant legume — to that list. If the blood pressure effects hold up in human studies, it could support development of bean-based functional foods for cardiovascular health.

Questions still open

• Would these peptides survive human digestion intact enough to still inhibit ACE?
• How do moth bean ACE-inhibiting peptides compare in potency to those from milk or fish sources?
• Could these peptides be concentrated into a supplement that meaningfully lowers blood pressure in humans?

Common questions

Read the original research

Purification, molecular docking and in vivo analyses of novel angiotensin-converting enzyme inhibitory peptides from protein hydrolysate of moth bean (Vigna aconitifolia (Jacq.) Màrechal) seeds.

International journal of biological macromolecules, 230, 123138

Citation

Bhadkaria, Amita; Narvekar, Dakshita Tanaji; Nagar, D P; Sah, Sangeeta Pilkwal; Srivastava, Nidhi; Bhagyawant, Sameer Suresh. (2023). Purification, molecular docking and in vivo analyses of novel angiotensin-converting enzyme inhibitory peptides from protein hydrolysate of moth bean (Vigna aconitifolia (Jacq.) Màrechal) seeds.. International journal of biological macromolecules, 230, 123138. https://doi.org/10.1016/j.ijbiomac.2023.123138